Would you like to learn more about this exciting joint venture between the MRC, AstraZeneca and the Milner Therapeutics Institute, and the application of arrayed CRISPR screening in uncovering novel genes and biology for disease? Please join this webinar for more information and a Q&A session about the on-going call for project proposals for the FGSL.
✅ Register now: cam-ac-uk.zoom.us/meeting/register/tZYtf-GoqjoiH9bfa43Fj9uAcCmVpNq0pI2_#/registration
The Milner Therapeutics Institute recently shared news of a new partnership with AstraZeneca and the Medical Research Council (MRC) that will establish a new state-of-the-art functional genomics screening laboratory (FGSL) at the Milner Therapeutics Institute. We're delighted that the call for proposals is now open!
The call is relevant to UK-based academics, small/medium-sized enterprises (SMEs) and pharma who have complex human in vitro models, such as organoids, co-culture models, etc., amenable to arrayed CRISPR screening. Through setting up collaborations with successful applicants, the FGSL aims to support academic researchers, SMEs and pharma to gain access to arrayed functional genomics screening to better understand the biology represented by the model and where applicable, for target identification.
Find more about the FGSL and the call for proposals at:
https://www.milner.cam.ac.uk/call-announced-for-project-prop...